These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29941342)

  • 21. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study.
    Menon P; Geevasinga N; Yiannikas C; Howells J; Kiernan MC; Vucic S
    Lancet Neurol; 2015 May; 14(5):478-84. PubMed ID: 25843898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood biomarkers and prognosis of amyotrophic lateral sclerosis.
    Sun J; Carrero JJ; Zagai U; Evans M; Ingre C; Pawitan Y; Fang F
    Eur J Neurol; 2020 Nov; 27(11):2125-2133. PubMed ID: 32557963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model.
    Sheean RK; McKay FC; Cretney E; Bye CR; Perera ND; Tomas D; Weston RA; Scheller KJ; Djouma E; Menon P; Schibeci SD; Marmash N; Yerbury JJ; Nutt SL; Booth DR; Stewart GJ; Kiernan MC; Vucic S; Turner BJ
    JAMA Neurol; 2018 Jun; 75(6):681-689. PubMed ID: 29507931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease.
    Banack SA; Dunlop RA; Cox PA
    Open Biol; 2020 Jun; 10(6):200116. PubMed ID: 32574550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.
    Byrne S; Elamin M; Bede P; Shatunov A; Walsh C; Corr B; Heverin M; Jordan N; Kenna K; Lynch C; McLaughlin RL; Iyer PM; O'Brien C; Phukan J; Wynne B; Bokde AL; Bradley DG; Pender N; Al-Chalabi A; Hardiman O
    Lancet Neurol; 2012 Mar; 11(3):232-40. PubMed ID: 22305801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.
    Chiò A; Calvo A; Bovio G; Canosa A; Bertuzzo D; Galmozzi F; Cugnasco P; Clerico M; De Mercanti S; Bersano E; Cammarosano S; Ilardi A; Manera U; Moglia C; Sideri R; Marinou K; Bottacchi E; Pisano F; Cantello R; Mazzini L; Mora G;
    JAMA Neurol; 2014 Sep; 71(9):1134-42. PubMed ID: 25048026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis.
    Pampalakis G; Mitropoulos K; Xiromerisiou G; Dardiotis E; Deretzi G; Anagnostouli M; Katsila T; Rentzos M; Patrinos GP
    Hum Mutat; 2019 Apr; 40(4):361-373. PubMed ID: 30556231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased Mitochondrial Function, Biogenesis, and Degradation in Peripheral Blood Mononuclear Cells from Amyotrophic Lateral Sclerosis Patients as a Potential Tool for Biomarker Research.
    Araujo BG; Souza E Silva LF; de Barros Torresi JL; Siena A; Valerio BCO; Brito MD; Rosenstock TR
    Mol Neurobiol; 2020 Dec; 57(12):5084-5102. PubMed ID: 32840822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.
    Conraux L; Pech C; Guerraoui H; Loyaux D; Ferrara P; Guillemot JC; Meininger V; Pradat PF; Salachas F; Bruneteau G; Le Forestier N; Lacomblez L
    PLoS One; 2013; 8(11):e79733. PubMed ID: 24224000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.
    Mitchell RM; Freeman WM; Randazzo WT; Stephens HE; Beard JL; Simmons Z; Connor JR
    Neurology; 2009 Jan; 72(1):14-9. PubMed ID: 18987350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers.
    Dorst J; Weydt P; Brenner D; Witzel S; Kandler K; Huss A; Herrmann C; Wiesenfarth M; Knehr A; Günther K; Müller K; Weishaupt JH; Prudlo J; Forsberg K; Andersen PM; Rosenbohm A; Schuster J; Roselli F; Dupuis L; Mayer B; Tumani H; Kassubek J; Ludolph AC
    EBioMedicine; 2023 Apr; 90():104521. PubMed ID: 36917918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.
    Vu LT; Bowser R
    Neurotherapeutics; 2017 Jan; 14(1):119-134. PubMed ID: 27933485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal biomarkers in amyotrophic lateral sclerosis.
    Huang F; Zhu Y; Hsiao-Nakamoto J; Tang X; Dugas JC; Moscovitch-Lopatin M; Glass JD; Brown RH; Ladha SS; Lacomis D; Harris JM; Scearce-Levie K; Ho C; Bowser R; Berry JD
    Ann Clin Transl Neurol; 2020 Jul; 7(7):1103-1116. PubMed ID: 32515902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
    Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
    Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
    OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis.
    Stoccoro A; Smith AR; Mosca L; Marocchi A; Gerardi F; Lunetta C; Cereda C; Gagliardi S; Lunnon K; Migliore L; Coppedè F
    Clin Epigenetics; 2020 Sep; 12(1):137. PubMed ID: 32917270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Joilin G; Gray E; Thompson AG; Talbot K; Leigh PN; Newbury SF; Turner MR; Hafezparast M
    Ann Med; 2022 Dec; 54(1):3069-3078. PubMed ID: 36314539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
    Gijselinck I; Van Langenhove T; van der Zee J; Sleegers K; Philtjens S; Kleinberger G; Janssens J; Bettens K; Van Cauwenberghe C; Pereson S; Engelborghs S; Sieben A; De Jonghe P; Vandenberghe R; Santens P; De Bleecker J; Maes G; Bäumer V; Dillen L; Joris G; Cuijt I; Corsmit E; Elinck E; Van Dongen J; Vermeulen S; Van den Broeck M; Vaerenberg C; Mattheijssens M; Peeters K; Robberecht W; Cras P; Martin JJ; De Deyn PP; Cruts M; Van Broeckhoven C
    Lancet Neurol; 2012 Jan; 11(1):54-65. PubMed ID: 22154785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers for amyotrophic lateral sclerosis.
    Bowser R; Cudkowicz M; Kaddurah-Daouk R
    Expert Rev Mol Diagn; 2006 May; 6(3):387-98. PubMed ID: 16706741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.